Pereira J, Ottevaere I, Serruys B, Guehring H, Ladel C, Lindemann S
J Pharmacokinet Pharmacodyn. 2024; 52(1):8.
PMID: 39704923
PMC: 11662058.
DOI: 10.1007/s10928-024-09958-z.
Sten S, Cardilin T, Antonsson M, Gennemark P
Clin Pharmacokinet. 2023; 62(12):1661-1672.
PMID: 37824025
PMC: 10684612.
DOI: 10.1007/s40262-023-01314-7.
Yokoyama M, Suzuki E, Oitate M, Watanabe N
Eur J Drug Metab Pharmacokinet. 2023; 48(5):541-552.
PMID: 37530974
DOI: 10.1007/s13318-023-00845-5.
Zou P
AAPS J. 2023; 25(4):53.
PMID: 37225958
DOI: 10.1208/s12248-023-00818-1.
Menochet K, Yu H, Wang B, Tibbitts J, Hsu C, Kamath A
MAbs. 2022; 14(1):2145997.
PMID: 36418217
PMC: 9704389.
DOI: 10.1080/19420862.2022.2145997.
Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
Pasquiers B, Benamara S, Felices M, Nguyen L, Decleves X
Int J Mol Sci. 2022; 23(21).
PMID: 36361546
PMC: 9657028.
DOI: 10.3390/ijms232112754.
A Simple Method for the Prediction of Human Concentration-Time Profiles and Pharmacokinetics of Antibody-Drug Conjugates (ADC) from Rats or Monkeys.
Mahmood I
Antibodies (Basel). 2022; 11(2).
PMID: 35735361
PMC: 9219807.
DOI: 10.3390/antib11020042.
Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies.
Zhu M, Olson K, Kirshner J, Toroghi M, Yan H, Haber L
Clin Transl Sci. 2022; 15(4):954-966.
PMID: 34997701
PMC: 9010254.
DOI: 10.1111/cts.13212.
A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey.
Mahmood I
Antibodies (Basel). 2021; 10(3).
PMID: 34562983
PMC: 8477747.
DOI: 10.3390/antib10030035.
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.
Germovsek E, Cheng M, Giragossian C
MAbs. 2021; 13(1):1964935.
PMID: 34530672
PMC: 8463036.
DOI: 10.1080/19420862.2021.1964935.
Comparison of Various Approaches to Translate Non-Linear Pharmacokinetics of Monoclonal Antibodies from Cynomolgus Monkey to Human.
Singh R, Moreno M, Stanimirovic D
Eur J Drug Metab Pharmacokinet. 2021; 46(4):555-567.
PMID: 34120326
DOI: 10.1007/s13318-021-00691-3.
Clinical Pharmacology of Antibody-Drug Conjugates.
Mahmood I
Antibodies (Basel). 2021; 10(2).
PMID: 34063812
PMC: 8161445.
DOI: 10.3390/antib10020020.
Estimation of Clearance and Bioavailability of Therapeutic Monoclonal Antibodies from Only Subcutaneous Injection Data in Humans Based on Comprehensive Analysis of Clinical Data.
Haraya K, Tachibana T
Clin Pharmacokinet. 2021; 60(10):1325-1334.
PMID: 33954956
PMC: 8505369.
DOI: 10.1007/s40262-021-01023-z.
Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice.
Nagayasu M, Ozeki K
Pharm Res. 2021; 38(4):583-592.
PMID: 33782838
DOI: 10.1007/s11095-021-03028-6.
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering.
Ko S, Jo M, Jung S
BioDrugs. 2021; 35(2):147-157.
PMID: 33608823
PMC: 7894971.
DOI: 10.1007/s40259-021-00471-0.
Interspecies Scaling of Antibody-Drug Conjugates (ADC) for the Prediction of Human Clearance.
Mahmood I
Antibodies (Basel). 2021; 10(1).
PMID: 33430196
PMC: 7839014.
DOI: 10.3390/antib10010001.
Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates.
Shivva V, Fink M, Lowe P
J Pharmacokinet Pharmacodyn. 2021; 48(2):295-303.
PMID: 33389522
DOI: 10.1007/s10928-020-09731-y.
Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy.
Nguyen H, Iskenderian A, Ehmann D, Jasper P, Zhang Z, Rong H
CPT Pharmacometrics Syst Pharmacol. 2020; 9(6):342-352.
PMID: 32419339
PMC: 7306616.
DOI: 10.1002/psp4.12518.
A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
Jones H, Zhang Z, Jasper P, Luo H, Avery L, King L
CPT Pharmacometrics Syst Pharmacol. 2019; 8(10):738-747.
PMID: 31464379
PMC: 6813168.
DOI: 10.1002/psp4.12461.
A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.
Yuan D, Rode F, Cao Y
Eur J Pharm Sci. 2019; 138:105032.
PMID: 31394258
PMC: 6824202.
DOI: 10.1016/j.ejps.2019.105032.